Experimental diabetic neuropathy: An update

Diabetologia

Volumn 42, Issue 7, 1999, Pages 773-788

  Sima, A A F ^a   Sugimoto, K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolism; Neuropathy; Pathogenesis; Pathology; Physiology

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; ESSENTIAL FATTY ACID; FREE RADICAL; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; NERVE GROWTH FACTOR; POLYOL; PROSTAGLANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; DIABETIC NEUROPATHY; GLYCATION; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC DISORDER; MOUSE; NEUROTROPISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; REVIEW; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HUMANS;

EID: 0032789870     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051227     Document Type: Review

References (163)

1. 1. Greene DA, Sima AAF, Feldman EL, Stevens MJ (1997) Diabetic neuropathy. In: Rifkin H, Porte D, Sherwin R (eds) Ellenberg and Rifkin diabetes mellitus. Appleton and Lange, Stanford Conn. pp 1009-1076
2. 2. Pickup JC, Williams G (1994) Chronic complications of diabetes. Blackwell Science, London
3. 3. Pirart J (1978) Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed. Diabetes Care 1: 168-188
4. 4. Thomas PK (1997) Clinical features and investigation of diabetic somatic peripheral neuropathy. Clin Neurosci 4: 341-345
5. 5. Yagihashi S (1995) Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab Metab Rev 11: 193-225
6. 6. Greene DA, Sima AAF, Stevens MJ et al. (1993) Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 9: 189-217
7. 7. Cameron NE, Cotter MA (1994) The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 10: 189-224
8. 8. Sima AAF, Ristic H, Merry A, Kamijo M, Lattimer SA, Stevens MJ, Greene DA (1996) The primary preventional and secondary interventative effects of acetyl-L-carnitine on diabetic neuropathy in the BB/W-rat. J Clin Invest 97: 1900-1907
9. 9. Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, Yao JK, Poduslo JF (1988) Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 319: 542-548
10. 10. Ishii DN (1995) Implications of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 20: 47-67
11. 11. Hall KE, Sima AAF, Wiley JW (1996) Opiate-mediated inhibition of calcium signaling is decreased in DRG neurons from the diabetic BB/W-rat. J Clin Invest 97: 1165-1172
12. 12. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 329: 977-986
13. 13. Sima AAF, Nathaniel V, Bril V, McEwen TAJ, Greene DA (1988) Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysjunction in human diabetic neuropathy. J Clin Invest 82: 349-364
14. 14. Sima AAF, Zhang W-X, Xu G, Sugimoto K, Wahren J (1998) C-peptide treatment has an ameliorating effect on type-1 diabetic neuropathy. Proc Diabetes Compl Conference Joslin 100th Anniversary, Boston, MA
15. 15. Ido Y, Vindigni A, Chang K et al. (1997) Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 777: 563-566
16. 16. Johansson B-L, Borg K, Fernquist-Forbes E, Odergren T, Remahl S, Wahren J (1996) C-peptide improves autonomic nerve function in patients with type-1 diabetes. Diabetologia 39: 687-695
17. 17. Heesom AE, Hibberd ML, Millward A, Demaine AG (1997) Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 46: 287-291
18. 18. Ko BC, Lam KS, Wat NM, Chung SS (1995) An (A-C)n dinucleotide repeat polymorphic marker at the 5′ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes 44: 727-732
19. 19. Yagihashi S, Kamijo M, Nagai K (1991) Peripheral neuropathy in diabetic animals: heterogenous expression of neuropathic patterns in different animal models. In: Shafrir E (ed) Frontiers in Diabetes Research. Lessons from animal diabetes, vol 3. Smith Gordon, London, pp 459-463
20. 20. Sharma AK, Richard PA (1999) Diabetic neuropathy in various animal models. In: Sima AAF (ed) Frontiers in Animal Diabetes Research. Chronic complication in diabetes. Harwood Acad. Publ., Amsterdam, pp 131-165
21. 21. Yagihashi S, Sugimoto K, Wada R (1994) Different neuropathic patterns between type-I and type-II animal models. In: Sakamoto N, Alberti KGMM, Hotta N (eds) Pathogenesis and Treatment of NIDDM and its Related Problems. Elsevier, Amsterdam, pp 401-405
22. 22. Sharma AK, Thomas PK (1987) Animal models: pathology and pathophysiology. In: Dyck PJ, Thomas PK, Ashbury AK, Winegrad AL, Porte D Jr (eds) Diabetic Neuropathy. Saunders, Philadelphia, pp 237-252
23. 23. Jakobsen J (1976) Axonal dwindling in early experimental diabetes. II. A study of isolated nerve fibres. Diabetologia 12: 539-546
24. 24. Yagihashi S, Kamijo M, Watanabe K (1990) Reduced myelinated fiber size correlates with loss of axonal neurofilaments in peripheral nerve of chronically streptozotocin diabetic rats. Am J Pathol 136: 1365-1373
25. 25. Medori R, Antilio-Gambetti L, Jenich H, Gambetti P (1988) Changes in axon size and slow axonal transport are related in experimental diabetic neuropathy. Neurology 38: 597-601
26. 26. Sima AAF, Zhang W-X, Tai J, Tze WJ, Nathaniel V (1988) Diabetic neuropathy in STZ-induced diabetic rat and effect of allogenic islet cell transplantation. Morphometric analysis. Diabetes 37: 1129-1136
27. 27. Yagihashi S, Kamijo M, Ido Y, Mirrless D (1990) Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy: ultrastructural and morphometric studies of sural nerve in streptozotocin-induced diabetic rats. Diabetes 39: 690-696
28. 28. Sugimura K, Windebank AJ, Natarajan V, Lambert EH, Schmid HH, Dyck PJ (1980) Interstitial hyperosmolality may cause axis cylinder shrinkage in streptozotocin diabetic nerve. J Neuropath Exp Neurol 39: 710-721
29. 29. Sharma AK, Bajada S, Thomas PK (1981) Influence of streptozotocin-induced diabetes on myelinated nerve fiber maturation and on body growth in the rat. Acta Neuropathol (Berl) 53: 257-265
30. 30. Cameron NE, Cotter MA (1999) Oxidative stress and abnormal lipid metabolism in diabetic complications. In: Sima AAF (ed) Frontiers in Animal Diabetes Research. Chronic Complications in Diabetes. Harwood, Amsterdam, pp 97-130
31. 31. Hellweg R, Hartung H-D (1990) Endogenous levels of nerve growth factor [NGF] are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 26: 258-267
32. 32. Verge VMK, Tetzlaff W, Bisby MA, Richardson PM (1990) Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons. J Neurosci 10: 2018-2025
33. 33. Nagata H, Brimijoin S, Low P, Schmelzer JD (1987) Slow axonal transport in experimental hypoxia and in neuropathy induced by p-bromophenylacetylurea. Brain Res 432: 319-326
34. 34. Schmidt RE, Scharp DW (1982) Axonal dystrophy in experimental diabetic neuropathy. Diabetes 32: 761-770
35. 35. Cameron NE, Cotter MA, Dines KC, Robertson S, Cox D (1993) The effects of evening primrose oil on peripheral nerve function and capillarization in streptozotocin-diabetic rats: modulation by the cyclo-oxygenase inhibitor flurbiprofen. Br J Pharmacol 109: 972-979
36. 36. Felten DL (1979) Spinal cord alterations in streptozotocin-induced diabetes. Anat Rec 193: 741
37. 37. Sidenius P, Jakobsen J (1980) Reduced perikaryal volume of lower motor and primary sensory neurons in early experimental diabetes. Diabetes 29: 182-186
38. 38. Sasaki H, Schmelzer JD, Zollman PJ, Low PA (1997) Neuropathology and blood flow of nerve, spinal roots and dorsal root ganglia in longstanding diabetic rats. Acta Neuropathol (Berl) 93: 118-128
39. 39. Russel JW, Windebank AJ, Schenone A, Feldman EL (1998) Insulin-like growth factor-1 prevents apoptosis in neurons after growth factor withdrawal. J Neurobiol 36: 455-467
40. 40. Marliss EB, Nakhooda AF, Poussier P, Sima AAF (1982) The diabetic syndrome of the BB-Wistar rat. Possible relevance to type-1 (insulin dependent) diabetes in man. Diabetologia 22: 225-232
41. 41. Sima AAF (1985) Can the BB-rat help to unravel diabetic neuropathy? Annotation. Neuropathol Appl Neurobiol 11: 253-264
42. 42. Yagihashi S, Sima AAF (1986) Diabetic autonomic neuropathy in the BB-rat. Ultrastructural and morphometric changes in parasympathetic nerves. Diabetes 35: 733-743
43. 43. Chakrabarti S, Zhang W-X, Sima AAF (1991) Optic neuropathy in the diabetic BB-rat. Adv Exp Med Biol 291: 257-264
44. 44. Sima AAF, Lattimer SA, Yagihashi S, Greene DA (1986) "Axo-glial dysjunction": a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic BB-rat. J Clin Invest 77: 474-484
45. 45. Greene DA, Chakrabarti S, Lattimer SA, Sima AAF (1987) Role of sorbitol accumulation and myoinositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic biobreeding rat. J Clin Invest 79: 1479-1485
46. 46. Sima AAF, Prashar A, Zhang W-X, Chakrabarti S, Greene DA (1990) Preventive effect of long term aldose reductase inhibition (Ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic BB-rat. J Clin Invest 85: 1410-1420
47. 47. Sima AAF, Brismar T (1985) Reversible diabetic nerve dysfunction. Structural correlates to electrophysiological abnormalities. Ann Neurol 18: 21-29
48. 48. Brismar T, Sima AAF (1981) Changes in nodal function in nerve fibres of the spontaneously diabetic BB-Wistar rat. Potential clamp analysis. Acta Physiol Scand 113: 499-506
49. +-channel displacement is associated with nerve conduction slowing in the chronically diabetic BB/W-rat. Prevention by an aldose reductase inhibitor. J Diabetes Complications 10: 192-200
50. 50. Magnani P, Cherian PV, Gould GW Greene DA, Sima AAF, Brosius FC III (1996) Glucose transporters in rat peripheral nerve: paranodal expression of GLUT1 and GLUT3. Metabolism 45: 1466-1473
51. 51. Merry AC, Yamamoto K, Sima AAF (1998) Imbalances in N-CAM, SAM and polysialic acid may underlie the paranodal ionchannel barrier defect in diabetic neuropathy. Diabetes Res Clin Prac 40: 153-160
52. 52. Sima AAF, Lorusso AC, Thibert P (1982) Distal symmetric polyneuropathy in the spontaneously diabetic BB-Wistar rat. An ultrastructural and teased fiber study. Acta Neuropathol (Berl) 58: 39-47
53. 53. Sima AAF, Yagihashi S (1986) Central-peripheral distal axonopathy in the spontaneously diabetic BB-rat: ultrastructural and morphometric findings. Diabetes Res Clin Prac 1: 289-298
54. 54. Zhang W-X, Chakrabarti S, Greene DA, Sima AAF (1990) Diabetic autonomic neuropathy in BB-rats: the effect of ARI-treatment on heart-rate variability and vagus nerve structure. Diabetes 39: 613-618
55. 55. Paro M, Prosdocimi M, Zhang W-X, Sutherland G, Sima AAF (1989) Autonomic neuropathy in the BB-rat. Alterations in bladder function. Diabetes 38: 1023-1030
56. 56. Sima AAF, Zhang W-X, Cherian PV, Chakrabarti S (1992) Impaired visual evoked potentials and primary axonopathy of the optic nerve in the diabetic BB/W-rat. Diabetologia 35: 602-607
57. 57. Sima AAF, Thibert P (1982) Proximal motor neuropathy in the BB-Wistar rat. Diabetes 31: 784-788
58. 58. Kamijo M, Merry AC, Cherian PV, Akdas G, Sima AAF (1996) Nerve fiber regeneration following axotomy in the diabetic BB/W-rat. The effect of ARI-treatment. J Diabetes Complications 10: 183-191
59. 59. Sima AAF, Merry AC, Levitan I (1997) Increased regeneration in ARI-treated diabetic nerve is associated with upregulation of IGF-1 and NGF receptors. Exp Clin Endocrinol Diabetes 105: 60-62
60. 60. Robertson DM, Sima AAF (1980) Diabetic neuropathy in the mutant mouse [C57/BL/Ks(db/db)]. A morphometric study. Diabetes 29: 60-67
61. 61. Moore SA, Peterson RG, Felten DL, Cartwright TR, O'Connor BL (1980) Reduced sensory and motor conduction velocity in 25-week-old diabetic [C57BL/Ks(db/db)] mice. Exp Neurol 70: 548-555
62. 62. Sharma AK, Thomas PK, Gabriel G, Stolinski C, Dockery P, Hollins GW (1983) Peripheral nerve abnormalities in the diabetic mutant mouse. Diabetes 32: 1152-1160
63. 63. Peterson RG, Sharma AK, Little L, Neel MA, Potter CG, Eichberg J (1988) Peripheral nerve abnormalities in Wistar fatty diabetic rats. In: Shaffir E, Renold AE (eds) Frontiers in Diabetic Research. Lessons from Animal Diabetes, vol 2. John Libbey, London
64. 64. Peterson RG, Little LA, Neel MA (1990) WKY fatty rat as a model of obesity and non-insulin-dependent diabetes mellitus. Institute of Laboratory Animal Resources News 32: 13
65. 65. Yagihashi S, Wada RI, Kamijo M, Nagai K (1993) Peripheral neuropathy in the WBN/Kob rat with chronic pancreatitis and spontaneous diabetes. Lab Invest 68: 296-307
66. 66. Sima AAF, Kommaraju SS, Hall D, Shy ME (1998) Absence of paranodal pathology in type-2 BB/Z-rats accounts for milder functional deficits compared to type-1 diabetic neuropathy. Diabetes 47: A136
67. 67. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AAF, Greene DA (1993) Osmotically induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 36: 608-614
68. 68. Greene DA, Chakrabarti S, Lattimer SA, Sima AAF (1987) Role of sorbitol accumulation and myoinositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic biobredding rat. J Clin Invest 79: 1479-1485
69. 69. Mayer JH, Tomlinson DR (1983) Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an ARI in streptozotocindiabetic rats. Diabetologia 25: 433-438
70. 70. Winegrad AL (1987) Banting Lecture 1986. Does a common mechanism induce the diverse complications of diabetes? Diabetes 36: 396-406
71. 71. Zhu X, Eichberg J (1990) 1,2-Diacyl-glycerol content and its arachidonyl-containing species are reduced in sciatic nerve from streptozotocin-induced diabetic rats. J Neurochem 55: 1087-1090
72. 72. Forcier NJ, Mizisin AP, Rimmer MA, Powell HC (1991) Cellular pathology of the nerve microenvironment in galactose intoxication. J Neuropath Exp Neurol 50: 235-255
73. +-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy. Diabetes 39: 663-666
74. 74. Ahlgren SC, Levine JD (1994) Protein kinase C inhibitors decrease hyperalgesia and C-fiber hyperexcitability in the streptozotocin-diabetic rat. J Neurophysiol 72: 684-692
75. 75. Williamson JR, Chang K, Frangos M et al. (1993) Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42: 801-813
76. +-ATPase activity independently of myo-inositol level by PGE 1 analogue OP-1206 α-CD in streptozotocin-induced diabetic rats. Diabetes 40: 726-730
77. 77. Yasuda H, Sonobe M, Hatanaka I et al. (1988) A new prostaglandin E1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozotocin-diabetic rats. Biochem Biophys Res Commun 150: 225-230
78. 78. Lowitt S, Malone JI, Salem AF, Korthals J, Benford S (1995) Acetyl-L-carnitine corrects altered peripheral nerve function in experimental diabetes. Metabolism 44: 677-680
79. 79. Hohman TC, Banas D, Basso M, Cotter MA, Cameron NE (1997) Increased oxidative stress in experimental diabetic neuropathy. Diabetologia 40 [Suppl 1]: A549
80. 80. Lou MF, Dickerson JE, Garadi R, York BM (1988) Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res 46: 517-530
81. 81. Tilton RG, Chang K, Nyengaard JR, van den Eden M, Kilo C, Williamson JR (1995) Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 44: 234-242
82. 82. Cameron NE, Cotter MA, Basso M, Hohman TC (1997) Comparison of the effects of inhibitors and aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol-pathway metabolites in streptozotocin-diabetic rats. Diabetologia 40: 271-281
83. 83. Schmidt RE, Dorsey DA, Beaudet LN, Plurad SB, Williamson JR, Ido Y (1998) Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy. J Neuropath Exp Neurol 57: 1175-1189
84. +-ATPase activity and motor conduction velocity in the streptozotocin diabetic rat. Metabolism 45: 865-872
85. 85. Hotta N, Koh N, Sakakibara F et al. (1996) Effect of proprionyl-L-carnitine on motor nerve conduction, autonomic cardiac function and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor. J Pharmacol Exp Ther 276: 49-55
86. 86. Cotter MA, Cameron NE, Keegan A, Dines KC (1995) Effects of acetyl-and proprionyl-L-carnitine on peripheral nerve function and vascular supply in experimental diabetes. Metabolism 44: 1209-1214
87. 87. Sima AAF, Srinivas PR, Kommaraju S, Venna S, Wahren J, Grunberger G (1998) Enhancement of insulin receptor activity by C-peptide. Diabetologia 41 [Suppl 1]: A177
88. 88. Mizisin AP, Powell C (1993) Schwann-cell injury is attenuated by aldose reductase inhibition in galactose intoxication. J Neuropath Exp Neurol 52: 78-86
89. 89. Kamijo M, Basso M, Cherian PV, Hohman TC, Sima AAF (1994) Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy. Diabetes Res Clin Pract 25: 117-129
90. 90. Yagihashi S, Yamagishi SI, Wada R et al. (1996) Galactosemic neuropathy in transgenic mice for human aldose reductase. Diabetes 45: 56-59
91. 91. Bianchi R, Marelli C, Marini P (1990) Diabetic neuropathy in db/db mice develops independently of changes in ATPase and aldose reductase. A biochemical and immunocyto-chemical study. Diabetologia 33: 131-136
92. 92. Sima AAF, Bril V, Nathaniel V et al. (1988) Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N Engl J Med 319: 548-555
93. 93. Van Dam PS, Van Asbeck BS, Erkeleus DW, Marx JJM, Gispen W-H, Bravenboer B (1995) The role of oxidative stress in neuropathy and other diabetic complications. Diabetes Metab Rev 11: 181-192
94. 94. Baynes JW (1991) Role of oxidative stress in the development of complications in diabetes. Diabetes 40: 405-412
95. 95. Wolff SP (1993) Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 49: 642-652
96. 96. McCord JM (1985) Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312: 159-163
97. 97. Hyslop PA, Hinshaw DB, Halsey WA Jr et al. (1988) Mechanism of oxidant mediated cell injury: the glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem 263: 1665-1675
98. 98. Maxfield EK, Cameron NE, Cotter MA, Dines KC (1993) Angiotensein II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats. Diabetologia 36: 1230-1237
99. 1 receptor antagonist. Am J Physiol 269: E530-E537
100. 100. Hallab M, Bled F, Ebrau JM et al. (1992) Elevated serum angiotensin I converting enzyme activity in type-1, insulin-dependent diabetic subjects with persistent microalbuminuria. Acta Diabetol 29: 82-85
101. 101. Cameron NE, Cotter MA, Archibald V, Dines KC, Maxfield EK (1994) Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin-diabetic rats. Diabetologia 37: 449-459
102. 102. Rubanyi GM, Polokoff MA (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmcol Rev 46: 325-415
103. A antagonist on neurovascular function in diabetic rats: interaction with the renin-angiotensin system. J Pharmacol Exp Ther 278: 1262-1268
104. 104. Stevens EJ, Tomlinson DR (1995) Effects of endothelin receptor antagonism with bosentan on peripheral nerve function in experimental diabetes. Br J Pharmacol 115: 373-379
105. 105. Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36: 1119-1125
106. 106. Faruqi R, de la Motte C, DiCorleto PE (1994) α-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 94: 592-600
107. 107. Low PA, Lagerlund TD, McManis PG (1989) Nerve blood flow and oxygen delivery in normal, diabetic and ischemic neuropathy. Int Rev Neurobiol 31: 355-438
108. 108. Cameron NE, Cotter MA, Robertson S (1992) Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 35: 12-18
109. 109. Olbrich A, Rosen P, Hilgers RD, Dhein S (1996) Fosinopril improves regulation of vascular tone in mesenteric bed of diabetic rats. J Cardiovasc Pharmacol 27: 187-194
110. 110. Gryglewski RJ, Palmer RMJ, Moncado S (1986) Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320: 454-456
111. 111. Tesfamariam B, Cohen RA (1992) Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 263: H321-H326
112. 112. Taylor PD, Poston L (1994) The effect of hyperglycemia on function of rat isolated mesenteric resistance artery. Br J Pharmacol 113: 801-808
113. 113. Keegan A, Cotter MA, Cameron NE (1997) Autonomic neuropathy, corpus cavernosum innervation and endothelial responses: diabetic defects prevented by alpha-lipoic acid in rats. J Peripheral Nerv System 2: 277
114. 114. Love A, Cotter MA, Cameron NE (1996) Effects of the sulphydryl donor N-acetyl-L-cysteine on nerve conduction, perfusion, maturation and regeneration following freeze damage in diabetic rats. Eur J Clin Invest 26: 698-706
115. 115. Love A, Cotter MA, Cameron NE (1997) Effects of alpha tocopherol on nerve conduction velocity and regeneration following freeze lesion in immature diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 355: 126-130
116. 116. Cameron NE, Cotter MA (1997) Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 46 [Suppl 2]: S31-S37
117. 117. Vlassara H (1994) Recent progress on the biologic and clinical significance of advanced glycosylatyion end products. J Lab Clin Med 124: 19-30
118. 118. Requena JR, Baynes JW (1999) Studies in animal models on the role of glycation and advanced glycation end-products (AGE:s) in the pathogenesis of diabetic complications: pitfalls and limitations. In: Sima AAF (ed) Frontiers in Animal Diabetes Research. Chronic complications in diabetes. Harwood, Amsterdam, pp 43-69
119. 119. Wells-Knecht KJ, Lyons TJ, McCance DR, Thorpe SR, Feather MS, Baynes JW (1994) 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 43: 1152-1156
120. 120. Glomb M, Monnier VM (1995) Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates in the Maillard reaction. J Biol Chem 270: 10017-10026
121. 121. Vlassara H, Brownlee M, Cerami A (1981) Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci USA 78: 5190-5192
122. 122. Vlassara H, Brownlee M, Cerami A (1983) Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. Diabetes 32: 670-674
123. 123. Weimbs T, Stoffel W (1994) Topology of CNS myelin proteolipid protein: evidence for the nonenzymatic glycosylation of extracytoplasmic domains in normal and diabetic animals. Biochemistry 33: 10408-10415
124. 124. Vlassara H, Brownlee M, Cerami A (1985) Recognition and uptake of human diabetic peripheral nerve myelin by macrophages. Diabetes 34: 553-557
125. 125. Ryle C, Leow CK, Donaghy M (1997) Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus. Muscle Nerve 20: 577-584
126. 126. Cullum NA, Mahon J, Stringer K, McLean WG (1991) Glycation of rat sciatic nerve tubulin in experimental diabetic mellitus. Diabetologia 34: 387-389
127. 127. Williams SK, Howarth NL, Devenny JJ, Bitensky MW (1982) Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proc Natl Acad Sci USA 79: 6546-6550
128. 128. Federoff JH, Lawrence D, Brownlee M (1993) Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 42: 509-513
129. 129. Takagi Y, Kashiwagi A, Tanaka Y, Asahina T, Kikkawa R, Shigeta Y (1995) Significance of fructose-induced protein oxidation and formation of advanced glycation end product. J Diabetes Complications 9: 87-91
130. 130. Dvornik D (1987) Aldose reductase inhibition. An approach to the prevention of diabetic complications. McGraw Hill, New York, NY
131. 131. Lal S, Szwergold BS, Taylor AH et al. (1995) Metabolism of fructose-3-phosphate in the diabetic rat lens. Arch Biochem Biophys 318: 191-199
132. 132. Phillips SA, Thornalley PJ (1993) The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 212: 101-105
133. 133. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48: 1-9
134. 134. Hoshi A, Takahashi M, Fujii J et al. (1996) Glycation and inactivation of sorbitol dehydrogenase in normal and diabetic rats. Biochem J 318: 119-123
135. 135. Soulis-Liparota T, Cooper ME, Dunlop M, Jerums G (1995) The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38: 387-394
136. 136. Phillips SA, Mirrlees D, Thornalley PJ (1993) Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor statil. Biochem Pharmacol 46: 805-811
137. 137. Arai K, Maguchi S, Fujii S, Ishibashi H, Oikawa K, Taniguchi N (1987) Glycation and inactivation of human Cu-Zn-superoxide dismutase. Identification of the in vitro glycated sites. J Biol Chem 262: 16969-16972
138. 138. Bierhaus A, Chevion S, Chevion M et al. (1997) Advanced glycation end product-induced activation of NF-χB is suppressed by α-lipoic acid in cultured endothelial cells. Diabetes 46: 1481-1490
139. ε-Carboxymethyllysine-protein adducts, one of advanced glycation end products. Diabetologia 40: 1380-1387
140. 140. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerani A (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632
141. 141. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K (1992) Effect of aminoguanidine of functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 41: 47-52
142. 142. Tomlinson DR, Fernyhough P (1999) Neurotrophism in diabetic neuropathy. In: Sima AAF (ed) Frontiers in Animal Diabetes Research. Chronic complications in diabetes. Harwood, Amsterdam, pp 167-182
143. 125I]-nerve growth factor in ileal mesenteric nerves vitro: effect of streptozotocin diabetes. Brain Res 378: 325-336
144. 144. DiStefano PS, Friedman B, Radziejewski C, Alexander C (1992) The neurotrophins BDNF, NT-3 and NGF display distinct patterns of retrograde axonal transport in peripheral and central neurons. Neuron 8: 983-993
145. 145. Fernyhough P, Brewster NJ, Diemel LT, Tomlinson DR (1993) Nerve growth factor mRNA in diabetic rat sciatic nerve; effects of neurtrophic factor treatment. Br J Pharmacol 110: 173P
146. 146. Fernyhough P, Carrington AL, Tomlinson DR (1992) Reduced nerve growth factor mRNA in skin of diabetic rats: effects of insulin. Br J Pharmacol 107: 462P
147. 147. Gold BG, Mobley WC, Matheson SF (1991) Regulation of axonal caliber, neurofilament content, and nuclear localization in mature sensory neurons by nerve growth factor. J Neurosci 11: 943-955
148. 148. Wang C, Li Y, Wible B, Angelides KJ, Ishii DN (1992) Effects of insulin and insulin-like growth factors on neurofilament mRNA and tubulin mRNA content in human neuroblastoma SH-Y5Y cells. Brain Res Mol Brain Res 13: 289-300
149. 149. Heumann R, Hengerer B, Brown M, Perry H (1991) Molecular mechanisms leading to lesion-induced increases in nerve growth factor synthesis. Ann NY Acad Sci 633: 581-582
150. 150. Whitworth IH, Terenghi G, Green CJ, Brown RA, Stevens E, Tomlinson DR (1995) Targeted delivery of nerve growth factor via fibronectin conduits assists nerve regeneration in control and diabetic rats. Eur J Neurosci 7: 2220-2225
151. 151. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA (1998) Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurol 51: 695-702
152. 152. Sima AAF, Levitan I, Ristic H, Kamijo M (1995) Nerve fiber regeneration in the spontaneously diabetic BB/W-rat. In: Hotta N, Greene DA, Ward JD, Sima AAf, Boulton AJM (eds) Diabetic Neuropathy: New Concepts and Insights. Elsvier Science BV, Amsterdam, pp 27-36
153. 153. Ishii DN, Lupien SB (1995) Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res 40: 138-144
154. 154. Fernyhough P, Mill JF, Roberts JL, Ishii DN (1989) Stabilization of tubulin mRNAs by insulin and insulin-like growth factor 1 during neurite formation. Mol Brain Res 6: 109-120
155. 155. Feldman EL, Sullivan KA, Kim B, Russell JW (1997) Insulin-like growth factors regulate neuronal differentiation and survival. Neurobiol Dis 4: 201-214
156. 156. Cheng HL, Feldman EL (1997) Insulin-like growth factor-1 (IGF-1) and IGF binding protein-5 in Schwann cell differentiation. J Cell Physiol 171: 161-167
157. 157. Lyons TJ (1991) Oxidised low density lipoproteins - a role in the pathogenesis of atherosclerosis in diabetes. Diabet Med 8: 411-419
158. 158. Horrobin DF, Carmichael H (1992) Essential fatty acids in relation to diabetes. In: Horrobin DF (ed) Treatment of diabetic neuropathy, a new approach. Churchill Livingstone, London
159. 159. Ward KK, Low PA, Schmelzer JD, Zochodne DW (1989) Prostacyclin and noradrenaline in peripheral nerve of chronic experimental diabetes in rats. Brain 112: 197-208
160. 160. Karasu C, Dewhurst M, Stevens EJ, Tomlinson DR (1995) Effects of antioxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia 38: 129-134
161. 161. Cameron NE, Cotter MA, Robertson S (1991) Essential fatty acid diet supplementation: effects on peripheral nerve and skeletal muscle function and capillarization in streptozotocin-induced diabetic rats. Diabetes 40: 532-539
162. 162. Dines KC, Cotter MA, Cameron NE (1995) Nerve function in galactosemic rats: effects of evening primrose oil and doxazosin. Eur J Pharmacol 281: 303-309
163. 163. Ido Y, McHowat J, Chang KC et al. (1994) Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-L-carnitine. Diabetes 43: 1469-1477